AJP - Endocrinology and Metabolism, Vol 249, Issue 4 392-E397, Copyright © 1985 by American Physiological Society

ARTICLES

Differential effects of forskolin on LH and GH release

W. S. Evans, T. H. Brannagan, E. R. Limber, M. J. Cronin, A. D. Rogol, E. L. Hewlett and M. O. Thorner

The effects of forskolin, an agent which increases intracellular levels of cAMP, on basal luteinizing hormone (LH) and growth hormone (GH) release and on gonadotropin-releasing hormone (GnRH)-stimulated LH release were documented. Continuously perifused dispersed anterior pituitary cells from female rats at random stages of the estrous cycle were used. Secretory rates of both LH and GH increased in a concentration-dependent manner in response to a 1-h challenge with 0.03, 0.1, 0.3, 1, or 3 microM forskolin. In response to 0.3 microM forskolin, maximum GH release was achieved within 15-20 min, after which secretion decreased. In contrast, LH release increased gradually, became maximal at 1.5-2 h, and remained constant until the forskolin was withdrawn. Cells exposed to 10 nM GnRH for 4 h exhibited a biphasic release of LH with the interphase nadir occurring at 30 min. The second phase of LH release was enhanced by simultaneous addition of forskolin with the GnRH. Whereas second phase release did not increase further, exposure of the cells to forskolin for 60 or 120 min before GnRH resulted in increased first-phase LH release. We suggest that, whereas our data are consistent with a role for cAMP in mediating the acute release of GH, cAMP may be involved in the process through which nonimmediately releasable LH becomes available for release.

This article has been cited by other articles:

				A. Nagy, A. V. Schally, G. Halmos, P. Armatis, R.-Z. Cai, V. Csernus, M. Kovacs, M. Koppan, K. Szepeshazi, and Z. Kahan Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin PNAS, February 17, 1998; 95(4): 1794 - 1799. [Abstract] [Full Text] [PDF]